Community Generated Content – EPOS
Co-founder Rolly Hayat of Hayats Pro speaks highly of the product he and his company received from EPOS not only in relation to the quality of the video conferencing technology but also the quality of customer support. Hayats Pro is a leading technology solutions provider and longtime EPOS partner. Most recently, they have implemented…
Latest
Articles
EPOS Transforms Hybrid Workplace for Salesforce
Salesforce is a top provider in CRM software with over 150 thousand customers. This large customer base requires their employees to be able to always function at the top of their game to provide the best possible service. With the modern workplace looking much different in the past few years, Salesforce, like many companies,…
Articles
EPOS Provides Best in Class Audio Experience to Travelers Insurance Users
Travelers Insurance was taking on a major project of outfitting its users worldwide with headsets for Skype as well as looking for an audio device for conference and breakout rooms. Guest Richard Pederzani, Technical Consultant Engineer for Travelers Insurance, explained that this would be a costly purchase of approximately thirty thousand headsets, and they…
Latest
Analyzing the Suppressive TME in In Vitro Based Assays
In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…
Targeting T Cells Within the Cancer Immunity Cycle
As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…
Inside Oncology Drug Development: Overcoming Resistance with Science
In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…